月度归档： 2026 年 4 月

HONG KONG, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"—offering insights into a company's pipeline potential and reflecting how industry veterans gauge the sector’s future.A clear signal of the company’s growth arrived in February 2026, when HighTide Therapeutics (2511.HK) announced a high-profile executive appointment: Dr. Filip Surmont joined the company as Chief Medical Officer (CMO).For professionals in the cardiovascular, renal, and metabolic fields, this is a name that carries real weight. Over a career spanning three decades, Dr. Surmont has held senior medical leadership roles at multinational giants including Wyeth, Pfizer, and AstraZeneca. Among his most notable contributions was his role in the global strategic development of the SGLT-2 inhibitor dapagliflozin — a landmark effort that required close collaboration across functions and geographies within a large multinational organization. As part of a talented cross-functional team, he helped shape the strategy that positioned dapagliflozin as a global metabolic blockbuster, ultimately reaching $8.405 billion USD in sales in 2025.Notably, just a few months earlier, HighTide Therapeutics' core product, HTD1801, had outperformed dapagliflozin across multiple key cardiovascular, renal, and metabolic endpoints in a head-to-head Phase III clinical trial for type 2 diabetes mellitus (T2DM).For Dr. Surmont, transitioning from managing a reigning "blockbuster" to joining a “challenger” Chinese biotech was far from coincidental. What drew him out of his comfort zone was not just HTD1801's strong glucose-lowering performance, but also the breakthrough potential this new molecular entity (NME) has shown in cardiovascular, kidney and metabolic (CKM) disease in general, and chronic kidney disease (CKD) more specifically — driven by a fundamentally differentiated pathophysiological mechanisms.I.Challenging Clinical Complacency in CKD: The Quest for True ReversalWithin the medical community, chronic kidney disease (CKD) has long been a source of frustration. Once the kidney function begins to decline, it typically deteriorates progressively and irreversibly over time, leaving most patients facing dialysis or kidney transplantation as an eventual outcome."There has long been a degree of complacency in CKD treatment among physicians, patients, and even caregivers," Dr. Surmont noted pointedly. "A mindset has taken hold that the progressive decline in renal function with age is inevitable. I’ve been striving to change this mindset throughout my career, both during my time at multinational pharmaceutical companies and now."Current standard treatments — including ACE inhibitors/ARBs and the widely used SGLT-2 inhibitors — have demonstrated efficacy in slowing disease progression, yet fall short of halting or reversing the underlying pathology. They can significantly reduce the rate of decline in the estimated glomerular filtration rate (eGFR), buying patients valuable time, but fail to alter the terminal trajectory towards kidney failure.Further complicating the clinical picture is the multi-factorial nature of CKD. Taking diabetic kidney disease (DKD) caused by T2DM as an example, besides pathophysiological factors driven by metabolic dysfunction, it is complicated by interconnected and highly complex factors such as hemodynamic perturbances, chronic inflammation, fibrosis, and other non-diabetic factors that fuel each other to worsen disease prognosis.Existing standard-of-care drugs often address only one dimension of the disease by regulating hemodynamics or a single metabolic pathway, making it difficult to comprehensively address the inflammatory damage in the renal microenvironment.II.Inside the Mechanism: Remodeling Renal Architecture via a Dual Metabolic and Anti-inflammatory PathwayThe emergence of HTD1801 provides a new key to breaking this deadlock.As an oral anti-inflammatory and metabolic modulator (AIMM) independently developed by HighTide Therapeutics, HTD1801 demonstrates a unique therapeutic potential at the microscopic level as compared to traditional drugs. Rather than relying on a single mechanism, it takes a "two-pronged" approach by activating AMPK (adenosine monophosphate-activated protein kinase) and inhibiting the NLRP3 inflammasome.Dr. Surmont has full confidence in the scientific logic underpinning this mechanism: "This drug acts simultaneously on two critical levels: beyond blood sugar, it improves overall metabolic efficiency at its source; at the same time, it directly suppresses the underlying chronic inflammation that drives organ damage."Taking a deep dive into its mechanism of action, HTD1801's dual mechanism precisely targets multiple microstructures within the kidney. "This is reflected across different renal compartments," Dr. Surmont explained. "From the filtering glomeruli and the structural interstitium to the reabsorptive tubules, and even podocytes—the vital gatekeepers of the filtration barrier, the dual action of AMPK activation and NLRP3 inhibition has demonstrated stronger-than-expected protective benefits."This mechanistic rationale, spanning from metabolic regulation to organ-level protection, has ultimately been validated by clinical data.At the 2025 American Society of Nephrology (ASN) Annual Meeting, HighTide Therapeutics presented as a late breaker Phase III clinical study data in T2DM patients with mild renal impairment. The results captured the industry's attention: compared with the placebo group, the HTD1801 group demonstrated a significant and sustainable difference in annualized eGFR slope of +9.81 ml/min/1.73 m²/year.In the eyes of nephrologists, a "positive slope" on the eGFR curve is a strong and unique signal, suggesting the possibility of early structural recovery."What we need to do next is confirm that this eGFR repair effect observed in DKD also holds true for CKD patients not driven by diabetes," Dr. Surmont revealed, indicating that relevant clinical studies are already underway, with more detailed data expected to validate this cross-etiology therapeutic potential.III.From "Rescue" to "Prevention": Advancing a Holistic Cardiorenal Metabolic (CKM) MindsetDr. Surmont brings to HighTide Therapeutics more than just clinical expertise; he brings a “game-changing” mentality that transcends a single-drug perspective.Another career-defining milestone for Dr. Surmont was his leadership role in helping reshape global asthma treatment guidelines. Historically, asthma management relied on short-acting bronchodilators for "rescue" only upon exacerbation of symptoms and shortness of breath. Dr. Surmont proposed and validated the "Anti-Inflammatory Reliever (AIR)" strategy a modern asthma management strategy that uses a combination inhaled corticosteroids and a bronchodilator as a reliever — treating both the acute bronchospasm and the underlying airway inflammation with every dose, in contrast to traditional short acting dilator-only relief.  This shift ultimately benefited approximately 120 million patients worldwide and reshaped treatment paradigms.Now, facing CKD, he sees the same opportunity for a paradigm-shifting breakthrough.Given HTD1801's strong potential to repair mild renal impairment, future clinical guidelines could reasonably recommend initiating treatments early, when eGFR is still at a relatively high level. By establishing a positive trajectory for renal function recovery early in the disease, there is hope that most patients can completely avoid the looming threat of dialysis.From a health-economics perspective, this would reallocate healthcare spending: shifting funds away from costly late-stage interventions (such as dialysis and heart failure rescue) towards highly cost-effective early treatment, thereby generating substantial healthcare cost savings for society and reducing patients’ financial burden for late-stage interventions.Dr. Surmont also strongly advocates for a holistic management approach to "Cardiovascular-Kidney-Metabolic (CKM)" health. As multifunctional drugs like HTD1801 continue to evolve, he believes physicians will move beyond the single-dimensional therapeutic mindset."My ideal scenario is that all physicians managing cardiovascular, metabolic, renal, hepatic, or even obesity issues would evaluate the patient with a holistic mindset," he says, pointing to the current siloed nature in clinical practice. " As an example eGFR monitoring is not always part of routine cardiological assessment, yet at the mechanistic level, cardiac and renal dysfunction are manifestations of the same underlying disease process — making an integrated view essential"He cited a successful experiment he led while promoting dapagliflozin in China: requiring cardiologists at partner hospitals to measure patients' eGFR during their consultations. By merely adding this simple cross-disciplinary action, the number of patients on guideline directed medical treatment tripled within six months.IV.A Buyer's Lens: The Booming BD Activity in CKD and HighTide Therapeutics’ Confidence in Value CreationAs a core member of the company's leadership team, Dr. Surmont also frequently examines HighTide Therapeutics' position through the lens of capital market and industry dynamics.Over the past two years, the global biopharmaceutical market has seen a surge in business development (BD) activity in the CKD field. In 2025, Roche announced a major collaboration with Zealand Pharma valued at up to $5.3 billion; multinational giants like Novartis, Boehringer Ingelheim, and Novo Nordisk have also been making significant investments to secure premium assets in the metabolic and renal disease space.Dr. Surmont, drawing on his extensive multinational experience, has a clear read on this "land grab" phenomenon: "The core driver is the massive profit potential and rapid growth in this field. Five years ago, the therapeutic arsenal here was relatively limited. Now, with breakthrough blockbusters like GLP-1RAs and SGLT-2i’s, the kidney disease landscape has been reshaped, yet there remains a residual risk is 60–80% of the original event burden.He further elaborated: "Even when patients are treated with four pillars of therapy (ACEi/ARBs, SGLT-2i’s, GLP-1RAs, MRAs), the complex underlying inflammatory mechanisms remain largely unaddressed, still leaving a significant gap in our ability to fully protect the kidney. This creates substantial pricing potential and broad combination therapy prospects for drugs with fundamentally new mechanisms like HTD1801.""Looking back at the history of SGLT-2 inhibitors, it took over a decade from approval to reaching 20%-25% guideline-directed clinical uptake. The slow progress was partly due to a lack of strong medical education and advocacy, and partly because of physicians and patients’ tendency to yield to the disease's natural trajectory."Now, having taken the helm as CMO of HighTide Therapeutics, Dr. Filip Surmont is poised to challenge the status quo and break this complacency with solid clinical data and a new medical narrative. For this drug—born from Chinese innovation with a global ambition—the voyage in the CKM field has only just begun. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TransNusa Launches New Scheduled Flight Connecting Jakarta With Lombok, Its World Class Surfing Island DestinationJAKARTA, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - TransNusa has announced the launch of a new direct scheduled flight connecting Jakarta and Lombok, further strengthening access to one of Indonesia’s key tourism and regional travel hubs.TransNusa Airlines Group Chief Executive Officer, Datuk Bernard Francis said that the introduction of this new route comes on the back of the airline’s focus to increase and strengthen connectivity while boosting domestic tourism.“Lombok is not only rapidly growing as a domestic and international tourist destination but the island is also the main gateway for tourism in the West Nusa Tenggara region through its Lombok International Airport,” Datuk Francis said, adding that Lombok attracts more than 1.2 million tourists annually.LOMBOK… Paradise of divers and surfersLombok is home to the diving haven Gili and Mount Rinjani National Park, one of Indonesia’s most iconic volcanic landscapes. The island offers dramatic trekking routes, cascading waterfalls and panoramic mountain views, attracting adventurers and nature lovers from around the world. Beyond its mountains, Lombok has also built a global reputation as a world-class surfing and diving destination, with pristine beaches, coral reef and consistent waves drawing surfers year-round.“TransNusa will initially operate 14 flights a week or two daily flights with the first scheduled flight departing Jakarta in the morning and the second in the afternoon,” Datuk Bernard said, adding that the sales of tickets for the new scheduled flight from Jakarta to Lombok started on 16 March 2026, with the inaugural flight scheduled for April 17, 2026.DATUK BERNARD FRANCIS… Lombok is the main gateway for tourism in the West Nusa Tenggara regionIn addition to this new launch, TransNusa has also increased the frequency of its Jakarta-Yogyakarta route with the aim to enhance and strengthen domestic connectivity, said Datuk Bernard.Flight DetailsTransNusa’s scheduled flight 8B 5161 will depart Soekarno–Hatta International Airport at 5:00am and arrive at Lombok International Airport at 8:00am. The returning service, 8B 5162, will depart Lombok International Airport at 8:30am and arrive in Jakarta at the Soekarno–Hatta International Airport at 9:30am. The second scheduled flight 8B 5165 will depart Jakarta’s Soekarno–Hatta International Airport at 03:00pm and arrive at the Lombok International Airport at 05:45pm. The returning service, 8B 5166 will depart Lombok International Airport at 06.15pm and arrive at the Soekarno–Hatta International Airport at 06.45pm.Ticket prices for TransNusa’s scheduled Jakarta-Lombok route start from as low as IDR899,000, CNY390, USD55, MYR225, AUD80, and SGD69. Tickets will be available for purchase at www.transnusa.co.id and on primary online travel agents’ platforms.Meanwhile, TransNusa’s additional scheduled flight for its Jakarta-Yogyakarta flight, 8B 5530, will depart Jakarta’s Soekarno–Hatta International Airport at 10.40am and arrive at the Yogyakarta International Airport at 11.50am. The flight, 8B 5531, will depart Yogyakarta at 01.20pm and arrive in Jakarta at 02.30pm.For its flights, TransNusa not only provides premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our SEAT passengers will enjoy check-in baggage of up to 20kgs,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.For the highest package, FLEXI-PRO, we provide services such as free baggage up to 30kgs, free to choose seats, free food, and drinks, priority at check-in and boarding counters.In addition, TransNusa also provides its FLEXI-PRO passengers with the flexibility to change their flight schedule without restrictions and obtain refund when needed,” added Datuk Bernard.TransNusa, which aims to ensure its passengers travel with ease and comfort, has also configured their A320s with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers.” stressed Datuk Bernard.TransNusa, A Short HistoryThe 3-year old TransNusa, led by aviation expert and veteran, Datuk Bernard, made waves in the aviation industry with its unique domestic and international business development and growth strategy.Within just 6 months of operations, in 2023, the airline, known then as a new player with new rules, launched its first international route between Jakarta and Kuala Lumpur, followed by the launch of scheduled flights between Jakarta and Singapore.TransNusa, which established itself as a Premium Service Carrier, made headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia to introduce new exciting routes. In 2023, during its first year of operations, TransNusa became the second Indonesian airline to receive approval to fly to China. In 2024, TransNusa became the first in the world to develop and introduce a new domestic route connecting Bali and Manado. In October 2025, TransNusa added yet another milestones by becoming the first Indonesian airline and second airline in the world to launch scheduled flights from Manado to Guangzhou, China.About TransNusaTransNusa Airline, is a Premium Service Carrier. In February 2024, the airline rebranded itself to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered. TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022.In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently based in Jakarta and Bali.On the international front, TransNusa flies to Singapore, Guangzhou, Kuala Lumpur, Perth, Shanghai, and Shenzhen. The airline became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model. Passengers can book their flights on the TransNusa website at www.transnusa.co.id, through any secure online travel agent, through authorized travel agents in Singapore and Indonesia.TransNusa’s Primary International Media Contact:Trina Thomas Rajtrina@myqaseh.org+60124992672 (whatsapp only) Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings’ (0697.HK) investments in the robotics sector are moving from early-stage positioning toward value realization.Management has disclosed that, by the end of 2025, the Company—through multiple industry funds under its management—had cumulatively invested more than RMB 2 billion across the broader robotics industry chain, covering more than 20 companies. According to the Chairman’s Statement for 2025, the valuation of the investment portfolio of the Beijing Robot Industry Development Investment Fund (Limited Partnership) increased by approximately fourfold. On that basis, the corresponding unrealized book gain is estimated at around RMB 8 billion. The robotics business has therefore become one of the most closely watched sources of incremental upside for Shoucheng Holdings in the near term.Based on disclosed projects, Shoucheng Holdings’ robotics strategy is not a series of isolated bets, but rather a systematic deployment across the industry chain. In the field of embodied intelligence and robotics, the Company has made concentrated investments in more than 20 leading companies, including Unitree Robotics, Noetix Robotics, Galbot, DEEP Robotics, Booster Robotics, and Galaxea AI. In the latest Chairman’s Statement, Chairman Zhao Tianyang characterized this approach as “track-level deployment”.Unlike some purely financial investors, Shoucheng Holdings is advancing its robotics business from simply “holding equity stakes” to “operating an industry”. Following an integrated path of “investment + operations + ecosystem,” the Company is building capabilities centered on “funds + scenarios + industry chain,” providing robotics companies with capital support, application scenarios, supply-chain integration, and commercialization pathways. On the offline channel side, its robotics consumer experience brand, Taozhu New Creation, has established five stores in Beijing, with locations including Shougang Park, Beijing Capital International Airport Terminals 2 and 3, and Wangfujing APM, among other core venues. To date, the Company has signed agreements with nearly 100 robotics companies as authorized agents.Market analysts note that the valuation logic for Shoucheng Holdings’ robotics business is transitioning from book valuations in the primary market toward more observable pricing in the capital markets. As a representative investment within Shoucheng Holdings’ robotics portfolio, Unitree Robotics—together with its IPO progress—provides the market with a clearer anchor for assessing the value of Shoucheng Holdings’ robotics assets.From a longer-term perspective, the data points of “more than RMB 2 billion invested, more than 20 companies covered, and portfolio valuation increasing approximately fourfold to around RMB 8 billion” already outline the basic contours of Shoucheng Holdings’ robotics strategy:At the front end, the Company secures leading projects through its funds.In the mid-stage, it accelerates commercialization through channels and service systems.At the back end, it opens up exit and re-rating opportunities through IPOs and capital operations.As projects such as Unitree Robotics move into the capital-market spotlight, the book value of Shoucheng Holdings’ robotics investments, its industrial synergy capabilities, and its subsequent monetization path are becoming increasingly clear. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PHILADELPHIA, PA AND WILMINGTON, DE, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - Datavault AI Inc. (NASDAQ:DVLT), an AI-driven data monetization, RWA tokenization, and Web 3.0 infrastructure company, and Demora Foundation, the Delaware-incorporated governing organization of the Demora Chain ecosystem (governed under JP3E Holdings Inc.), today announced the execution of a Technology Integration Agreement establishing Datavault AI as the formal AI data intelligence and RWA tokenization technology partner for the K-Entertainment & K-Wave Global Platform - the integrated K2Global + Demora Foundation ecosystem that converts Korean cultural IP, live entertainment, and K-Wave soft power into institutional-grade, on-chain financial products, deployed across three US Innovation K-Wave Cities: Atlanta (GA), Dallas (TX), and New York Tri-State.K-WAVE AUDIENCE SCALE200M+Global Hallyu Fans · 156 Countries$40B+K-Wave Annual Economic Impact (KOFICE 2024)$14B+K-Pop Revenue 2025E (Live + Streaming + Merch)120M+Dedicated K-Pop Concert Fans Globally500+Korean SMBs · 8 K-Wave Sectors · K2Global Mandate$3B+K-Entertainment Tokenizable Pipeline (DMR-LIVE)3US Innovation K-Wave Cities (ATL · DAL · NY Tri-State)8-14%Target DMR-LIVE Token Yield (Annualized)The Agreement deploys Datavault AI's full enterprise AI stack - Data Vault®, DataValue®, DataScore®, and Information Data Exchange® (IDE) Digital Twin - as the AI data intelligence and RWA/VWA tokenization backbone of Demora Chain, purpose-built to score, value, credentialize, and tokenize K-Entertainment assets - including K-Pop concert revenues, K-Drama IP royalties, K-content digital rights, K-Beauty brands, and K-Food franchises - as yield-bearing instruments settled in DMR (apex RWA) and GMMT (VWA layer) on Demora's dual OP Stack Layer 2.The K-Entertainment Opportunity - 200M+ Fans, $11B-$16B Annual Event Revenue, $3B+ Tokenizable PipelineThe Korean Wave (Hallyu) is the most scalable cultural export engine in the world - and the foundational demand signal for the entire DVLT × Demora Foundation partnership. With 200M+ Hallyu fans across 156 countries generating over $40B in annual economic impact, K-Entertainment represents an institutional-scale, pre-qualified audience base no other RWA protocol can access.K-Entertainment Audience & Tokenizable Pipeline - By VerticalK-Wave VerticalGlobal Fan BaseAnnual Event Revenue Est.Digital / Streaming LayerDMR-LIVE Tokenization OpportunityK-Pop Live Concerts & Tours120M+ dedicated fans$6B - $8B globallyWeverse, YouTube, streaming rights$1.5B+ addressableK-Drama & Film IP Events80M+ drama viewers$2B - $3B IP + premiere circuitNetflix, Disney+, local OTT licensing$600M+ addressableK-Food & Culinary Festivals50M+ global K-Food consumers$800M - $1.2B festivals/franchiseExport brands, franchise licensing$250M+ addressableK-Beauty Brand Events & Launches60M+ active K-Beauty consumers$1B - $1.5B experiential marketingD2C, influencer, brand collab$300M+ addressableGaming, Esports & Webtoon Festivals40M+ K-gaming & esports fans$1.2B - $2B event + IPStreaming, IP licensing, game merch$400M+ addressableTOTAL K-Entertainment TAM200M+ Hallyu Fans (composite)$11B - $16B annual event revenue$5B+ digital overlay$3B+ tokenizable pipelineDMR-LIVE Protocol - K-Entertainment RWA Tokenization EngineAt the core of the DVLT × Demora Foundation partnership is DMR-LIVE - the K-Entertainment RWA tokenization protocol that converts live event cash flows (ticket receivables, venue revenues, VIP hospitality, IP/sponsorship contracts) into yield-bearing digital assets settled on Demora Chain. Datavault AI provides the AI data intelligence layer that makes DMR-LIVE institutional-grade.DMR-LIVE - Projected Deployment & Deal ScalePhase 1 · 0-6 MonthsPilot Launch5-10 K-Wave flagship events (US + Korea)DMR-LIVE token launch on Demora Chain$25M - $50M initial pool issuance500K - 1M live attendeesInstitutional LP onboarding (Reg D)Phase 2 · 6-18 MonthsScale & Liquidity20-40 multi-genre eventsUS, Korea, Africa, SE Asia$100M - $300M issuance target3M - 8M live + digital viewersSWF / Ex-Im institutional channelPhase 3 · 18-36 MonthsGlobal Integration100+ events per annual cycleGlobal deployment (20+ countries)$300M+ annual issuance run-rate15M - 30M annual audienceNASDAQ SPAC pathway for K2GlobalDatavault AI - Powering K-Entertainment IP Intelligence & TokenizationDatavault AI's enterprise platform serves as the data intelligence layer that transforms K-Entertainment assets from illiquid cultural IP into institutional-grade, on-chain financial products:K-Pop & Content IP - IDE Digital Twin & NIL CredentialingOn-chain digital twin representations of K-Pop artist brands, K-Drama IP rights, digital content royalties, and NIL (Name, Image, Likeness) credentials - enabling programmable IP monetization and VWA issuance on GMMT layer.K-Entertainment Asset Valuation - DataScore® AI AgentsAI-based scoring and valuation of K-Pop artist tour revenue forecasts, K-Drama IP licensing streams, K-content streaming rights, and live event cash flow projections - providing the institutional-grade data oracle powering DMR-LIVE token pricing.Franchise & Brand Asset Scoring - DataValue®Comprehensive valuation scoring for K-Beauty brands, K-Food franchise systems, and K-Fashion design IP - preparing these assets for DMR-denominated RWA tokenization and cross-border distribution settlement on Demora Chain.Entertainment & Sports Vertical - HPC Software LicensingHigh-performance compute infrastructure for real-time K-Wave asset valuation, streaming rights scoring, and DMR-denominated tokenization at institutional scale - spanning K-Pop, K-Drama, K-Gaming, and K-Esports verticals.Provenance & Compliance - Data Vault® + Web 3.0 Immutable MetadataEnterprise data management and immutable provenance framework for K-Entertainment IP registrations, royalty flow traceability, and institutional-grade KYC/AML compliance aligned with Demora Chain's DMR settlement requirements.Global Digital Infrastructure Platform - Three-Layer ArchitectureThe DVLT partnership operates across the three-layer JP3E platform architecture - with K-Entertainment as the lead vertical:Platform LayerRole & DVLT Integration PointK2Global (Layer 3 - Application)Asset origination layer: 500+ Korean SMBs across 8 K-Wave sectors. K-Entertainment leads - K-Pop concert IP, K-Drama rights, K-Beauty brands, K-Food franchises. K2Global identifies the real-world and IP assets that DVLT's DataScore® and IDE Digital Twin will score, value, and credentialize for tokenization on Demora Chain.JP3E Holdings (Structure & Access)Institutional governance and capital structure layer. Structures regulatory compliance (Clean Wall separation), OTC → NASDAQ pathway, and sovereign capital access. DVLT's KYC/AML-compliant Web3 data management integrates at this governance layer.Demora Foundation (Layer 1 - Tokenize & Liquidate)Converts illiquid K-Entertainment and K-Wave infrastructure assets into tradable DMR-denominated RWA and GMMT-powered VWA instruments via Demora Chain's dual OP Stack Layer 2. DVLT's HPC-powered tokenization platform and immutable metadata framework are the core technology input at this layer - enabling LP waterfall yield + DMR token upside.K-Wave Cities Deployment - DVLT Integration by SectorThe Technology Integration Agreement positions Datavault AI as the enterprise data intelligence and tokenization technology partner across all eight K-Wave growth sectors in three US Innovation Cities - with K-Entertainment as the flagship commercial vertical:K-Wave SectorDVLT Platform ApplicationEntertainment - K-Pop, Drama IP, Digital Content & MediaFLAGSHIP VERTICAL - IDE Digital Twin & NIL credentialing for K-Pop artist IP, K-Drama content rights, and digital royalty tokenization as VWA on GMMT; DataScore® for AI-based content asset valuation and live event revenue forecasting; DMR-LIVE protocol integration for K-Pop concert receivables tokenization as RWA on DMRFood & Beverage - K-Food Franchise, Cuisine & ExportDataValue® for franchise system and supply chain asset scoring; J1Manna DMR RWA settlement for cross-border distribution contracts through Innovation City hubsBeauty & Cosmetics - K-Beauty Brands, Skincare & BiotechDVLT healthcare HPC licensing applied to K-Beauty O-Min, biotech supply chains; IDE Digital Twin for K-Longevity (NovocellBio NK cell) clinical supply RWA tokenizationTechnology / AI - IoT, Robotics & BlockchainDataScore® AI agents for KORECEN biometric patent (13 KIPO finger-vein) valuation as RWA; DVLT Web 3.0 enterprise data management for IoT/robotics SMB IP assetsManufacturing - Advanced Materials, EV Components & BatteriesDVLT immutable metadata for critical minerals provenance; IDE Digital Twin for K-Defense, dual-use hardware supply chain traceability on DMRHealthcare / Bio - Pharmaceuticals, Medical Devices & TelehealthDVLT healthcare HPC licensing and DataValue® for NovocellBio NK cell manufacturing capacity and clinical supply agreement tokenization as K-Longevity RWA on DMRFashion - Contemporary Design & Textile InnovationIDE NIL credentialing for brand and design IP; DataScore® for O-Min fashion IP asset valuation as VWA on GMMT; cross-border distribution RWA on DMREducation / EdTech - E-Learning Platforms & Global CertificationDVLT Web 3.0 data management for SaaS-model EdTech platform data assets; DataScore® for certification IP valuation feeding Demora flywheel programmable yield via DMRStatements"Datavault AI was built for exactly this moment - when AI-powered data intelligence meets institutional blockchain infrastructure at a global scale. The K2Global Innovation K-Wave platform, with K-Entertainment as its flagship vertical, represents one of the most compelling real-world asset mandates in the market today: 200M+ Hallyu fans, $14B+ in K-Pop revenue, 500+ Korean SMBs, three US Innovation Cities, and a two-token blockchain architecture built for institutional settlement. Our Data Vault®, DataValue®, DataScore®, and Digital Twin platforms are the intelligence layer that transforms K-Entertainment IP - from K-Pop concert revenues and K-Drama royalties to K-Beauty brands and K-Food franchises - from illiquid cultural assets into scalable, liquid digital financial products. We are proud to be the technology partner of choice for the JP3E platform."- Nathaniel Bradley, CEO, Datavault AI Inc. (NASDAQ: DVLT)"The Datavault AI partnership is a defining moment for the Global Digital Infrastructure Platform - and specifically for DMR-LIVE, our K-Entertainment RWA tokenization protocol. K-Entertainment is not merely one of eight K-Wave sectors; it is the cultural demand engine that drives all of them. With 200M+ Hallyu fans, $40B+ in annual K-Wave economic impact, and a $3B+ tokenizable K-Entertainment pipeline, DVLT's AI-powered data valuation, Digital Twin technology, and enterprise tokenization stack provide precisely the intelligence infrastructure required to convert Korean cultural IP into institutional-grade, on-chain financial products at global scale. Together, we are building the operating system for K-Wave infrastructure finance."- John K. Park, Chairman & CEO, Demora Foundation / JP3E Holdings Inc.About Datavault AI Inc. (NASDAQ: DVLT)Datavault AI Inc. (NASDAQ:DVLT) is an AI-driven data monetization, RWA tokenization, and Web 3.0 infrastructure company headquartered at One Commerce Square, 2005 Market Street, Suite 2400, Philadelphia, PA 19103. DVLT provides enterprise-grade platforms including Information Data Exchange® (Digital Twin / NIL credentialing), Data Vault®, DataValue®, and DataScore® AI agents, and HPC-powered data valuation and secure monetization infrastructure spanning fintech, healthcare, real estate, and sports & entertainment verticals - including the full K-Entertainment sector. CEO: Nathaniel Bradley. Website: www.datavaultsite.comAbout Demora FoundationDemora Foundation is the institutional governance entity of Demora Chain - a dual OP Stack Layer 2 on Ethereum (target: 560,000+ TPS, USD1 gas model) designed for stablecoin finance, RWA tokenization, and VWA (Virtual Wealth Asset) creation at institutional scale. Demora Foundation governs the DMR-LIVE K-Entertainment RWA tokenization protocol as the flagship product of its K2Global Innovation K-Wave Cities deployment. Demora Foundation is incorporated in Delaware and governed under JP3E Holdings Inc. Website: demora.foundationMedia Contacts:John K. Park, Chairman & CEO - JP3E Holdings Inc. / Demora FoundationJohn.park@jp3e.com | www.jp3e.com | demora.foundationAlan Wallace, Head of Public Relations - Datavault AI / marketing@dvlt.aiInvestor ContactEdward Barger, VP, Investor Relations - Datavault AI, ir@dvlt.ai - ebarger@dvlt.aiSOURCE: Datavault AI Inc Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

宾夕法尼亚州费城及特拉华州威尔明顿, 2026年4月2日 - (亚太商讯 via SeaPRwire.com) - 人工智能驱动的数据变现、RWA代币化及Web 3.0基础设施公司Datavault AI Inc.（纳斯达克代码：DVLT），与特拉华州注册的Demora Chain生态系统管理组织Demora Foundation（由JP3E Holdings Inc.管理） 今日宣布签署技术整合协议，确立Datavault AI作为“K-娱乐与韩流全球平台”（即整合K2Global与Demora Foundation生态系统的平台）的正式AI数据智能及RWA代币化技术合作伙伴。该平台致力于将韩国文化IP、现场娱乐及韩流软实力转化为机构级别的链上金融产品，并部署于美国三大创新韩流城市： 亚特兰大（佐治亚州）、达拉斯（得克萨斯州）以及纽约三州地区。K-WAVE 受众规模2亿+全球韩流粉丝 · 156个国家400亿美元+K-Wave年度经济影响（韩国文化产业振兴院2024年数据）140亿美元+ 2025年K-Pop预计收入 （现场演出 + 流媒体 + 周边商品）1.2亿+ 全球忠实K-Pop演唱会粉丝500+ 韩国中小企业 · 8大韩流产业领域 · K2Global战略30亿美元+ K-娱乐可代币化项目储备（DMR-LIVE）3 美国创新韩流城市（亚特兰大·达拉斯·纽约三州地区）8-14% DMR-LIVE代币目标收益率（年化）该协议部署了Datavault AI的完整企业级AI技术栈——Data Vault®、DataValue®、DataScore®以及Information Data Exchange®（IDE）数字孪生技术——作为Demora Chain的AI数据智能及RWA/VWA代币化核心架构。该架构专为对K-娱乐资产进行评分、估值、认证及代币化而设计，涵盖K-Pop演唱会收入、韩剧IP版税、 韩流内容数字版权、韩妆品牌及韩式餐饮特许经营权——将其转化为以 DMR（顶级 RWA）和 GMMT（VWA 层）结算的生息工具，部署于 Demora 的双 OP 堆栈 Layer 2 上。韩流娱乐机遇——2 亿+粉丝、110 亿至 160 亿美元年度活动收入、30 亿+美元可代币化项目储备韩流（Hallyu）是全球最具可扩展性的文化出口引擎，也是DVLT × Demora基金会整个合作关系的根本需求信号。韩流粉丝遍布156个国家，总数超过2亿，每年创造超过400亿美元的经济影响，K-娱乐代表着一个机构级别的、经过预先筛选的受众群体，这是其他任何RWA协议都无法触及的。K-娱乐受众与可代币化项目储备——按垂直领域划分韩流垂直领域全球粉丝群体年度活动收入估算数字/流媒体层DMR-LIVE 代币化机遇 K-Pop 现场演唱会及巡演1.2亿+忠实粉丝 全球60亿至80亿美元Weverse、YouTube、流媒体版权 15亿美元+可触达市场韩剧及电影IP活动8000万+剧集观众20亿至30亿美元IP及首映巡回Netflix、Disney+、本地OTT授权6亿美元+可触达市场 韩餐与美食节5000万+全球韩餐消费者8亿至12亿美元 节庆/特许经营出口品牌、特许经营授权 2.5亿美元+可触达市场韩妆品牌活动与新品发布6000万+活跃韩妆消费者10亿至15亿美元体验式营销D2C、网红营销、品牌联名3亿美元+潜在市场规模游戏、电竞及网络漫画节4000万+韩式游戏与电竞粉丝12亿至20亿美元的活动及IP直播、IP授权、游戏周边4亿+美元可触达市场 韩流娱乐总目标受众2亿+韩流粉丝（综合）110亿至160亿美元年度活动收入50亿美元以上数字增值30亿美元以上可通证化项目储备DMR-LIVE协议——韩流娱乐RWA代币化引擎DVLT 与 Demora 基金会合作的核心是 DMR-LIVE——这一韩国娱乐 RWA 代币化协议，可将现场活动现金流（门票应收款、场馆收入、VIP 接待、IP/赞助合同）转化为基于 Demora Chain 结算的生息数字资产。Datavault AI 提供的 AI 数据智能层，使 DMR-LIVE 达到机构级标准。DMR-LIVE - 预计部署与交易规模第一阶段 · 0-6个月试点启动5-10场K-Wave旗舰活动（美国 + 韩国）在 Demora Chain 上推出 DMR-LIVE 代币初始池发行量 2,500 万至 5,000 万美元50 万至 100 万现场观众机构流动性提供商（LP）接入（Reg D）第二阶段 · 6-18 个月规模与流动性20-40 场多类型活动美国、韩国、非洲、东南亚1 亿至 3 亿美元发行目标300 万至 800 万现场及线上观众主权财富基金（SWF）/进出口银行（Ex-Im）机构渠道第三阶段 · 18-36个月全球整合每年100余场活动全球部署（20多个国家）3亿美元以上年度发行规模1500万至3000万年度受众K2Global的纳斯达克SPAC上市路径Datavault AI——赋能韩流娱乐IP智能分析与通证化Datavault AI的企业级平台作为数据智能层，将韩流娱乐资产从缺乏流动性的文化IP转化为机构级别的链上金融产品：K-Pop及内容IP——IDE数字孪生与NIL凭证认证通过链上数字孪生技术，对K-Pop艺人品牌、韩剧IP权益、数字内容版税及NIL（姓名、肖像、形象）凭证进行建模——从而在GMMT层实现可编程的IP变现及VWA代币发行。韩流娱乐资产估值 - DataScore® AI 代理基于 AI 的评分与估值，涵盖 K-Pop 艺人巡演收入预测、韩剧 IP 授权流、韩流内容流媒体版权以及现场活动现金流预测——提供机构级数据预言机，驱动 DMR-LIVE 代币定价。特许经营与品牌资产评分 - DataValue®针对韩系美妆品牌、韩式餐饮特许经营体系及韩系时尚设计知识产权进行全面估值评分，为这些资产在Demora Chain上进行以DMR为计价单位的RWA代币化及跨境分发结算做好准备。娱乐与体育垂直领域 - HPC软件授权面向机构级规模的高性能计算基础设施，用于韩流资产的实时估值、流媒体版权评分及DMR计价的代币化——覆盖K-Pop、韩剧、K-Gaming及K-Esports垂直领域。溯源与合规 - Data Vault® + Web 3.0不可篡改元数据面向K-娱乐知识产权注册、版税流向追溯以及符合Demora Chain DMR结算要求的机构级KYC/AML合规的企业数据管理与不可篡改溯源框架。全球数字基础设施平台 - 三层架构DVLT 合作伙伴关系基于三层 JP3E 平台架构运作，以韩流娱乐为主要垂直领域：平台层角色与 DVLT 集成点K2Global（第 3 层 - 应用层）资产生成层：覆盖8大韩流领域的500多家韩国中小企业。K-Entertainment主导——K-Pop演唱会IP、韩剧版权、K-Beauty品牌、K-Food特许经营权。K2Global识别现实世界及IP资产，由DVLT的DataScore®和IDE数字孪生进行评分、估值及凭证化，以便在Demora Chain上进行代币化。JP3E Holdings（架构与准入）机构治理与资本结构层。构建合规架构（清洁墙隔离）、场外交易→纳斯达克上市路径，并实现主权资本准入。DVLT符合KYC/AML要求的Web3数据管理在此治理层实现集成。Demora基金会（第1层——代币化与变现）通过Demora Chain的双OP堆栈Layer 2，将非流动性的K-娱乐及K-Wave基础设施资产转化为可交易的DMR计价RWA及GMMT驱动的VWA金融工具。DVLT的HPC驱动代币化平台与不可篡改的元数据框架是该层的核心技术输入——实现LP级联收益+DMR代币增值空间。                  K-Wave城市部署——按行业领域整合DVLT该技术整合协议确立了Datavault AI作为企业数据智能与代币化技术合作伙伴的地位，覆盖美国三大创新城市中的全部八个K-Wave增长领域，其中K-娱乐作为旗舰商业垂直领域：K-Wave领域DVLT平台应用娱乐——K-Pop、电视剧IP、数字内容与媒体旗舰垂直领域——IDE数字孪生及NIL认证，用于K-Pop艺人IP、韩剧内容版权及数字版税代币化（作为GMMT上的VWA）；DataScore®用于基于AI的内容资产估值及现场活动收入预测；DMR-LIVE协议集成，用于K-Pop演唱会应收账款代币化（作为DMR上的RWA）食品与饮料 - 韩式餐饮特许经营、美食及出口DataValue® 用于特许经营体系及供应链资产评分；通过创新城枢纽，利用 J1Manna DMR RWA 结算跨境分销合同美容与化妆品 - 韩系美妆品牌、护肤及生物技术DVLT医疗保健HPC许可应用于韩系美妆品牌O-Min及生物技术供应链；IDE数字孪生技术用于K-Longevity（NovocellBio NK细胞）临床供应RWA代币化科技/人工智能 - 物联网、机器人与区块链DataScore® AI代理用于KORECEN生物识别专利（13项KIPO指静脉专利）作为RWA的估值；DVLT Web 3.0企业数据管理，用于物联网/机器人领域中小企业的知识产权资产制造业 - 先进材料、电动汽车零部件及电池DVLT不可篡改元数据用于关键矿产溯源；IDE数字孪生技术应用于K-Defense，基于DMR的双用途硬件供应链可追溯性医疗保健 / 生物科技 - 制药、医疗器械及远程医疗DVLT医疗保健HPC授权及DataValue®，用于NovocellBio NK细胞生产能力与临床供应协议的代币化，作为K-Longevity基于DMR的RWA时尚——当代设计与纺织创新IDE NIL 品牌及设计知识产权认证；DataScore® 基于 GMMT 模型对 O-Min 时尚知识产权资产进行 VWA 估值；基于 DMR 模型对跨境分销进行 RWA 估值教育/教育科技 - 在线学习平台与全球认证DVLT Web 3.0 数据管理，用于 SaaS 模式教育科技平台的数据资产；DataScore® 用于认证知识产权估值，通过 DMR 为 Demora 飞轮提供可编程收益声明“Datavault AI正是为这一时刻而生——当人工智能驱动的数据智能与全球规模的机构级区块链基础设施相遇之时。以K-娱乐为旗舰垂直领域的K2Global创新K-Wave平台，代表了当今市场上最具吸引力的现实资产项目之一：2亿+韩流粉丝、140亿美元+的K-Pop收入、500+家韩国中小企业、三个美国创新城市，以及专为机构结算打造的双代币区块链架构。我们的Data Vault®、DataValue®、DataScore®及Digital Twin平台构成了智能层，将K-Entertainment知识产权——从K-Pop演唱会收入、韩剧版税到K-Beauty品牌及K-Food特许经营——从非流动性文化资产转化为可扩展、高流动性的数字金融产品。我们很荣幸能成为JP3E平台的首选技术合作伙伴。"- 纳撒尼尔·布拉德利（Nathaniel Bradley），Datavault AI Inc.（纳斯达克代码：DVLT）首席执行官“与Datavault AI的合作是全球数字基础设施平台——特别是我们的K-娱乐RWA代币化协议DMR-LIVE——的一个关键时刻。K-娱乐不仅仅是八大韩流产业领域之一，它是驱动所有这些领域的文化需求引擎。凭借2亿余韩流粉丝、400亿美元以上的年度K-Wave经济影响，以及30亿美元以上的可代币化K-娱乐项目储备，DVLT的AI驱动数据估值、数字孪生技术及企业级代币化技术栈，恰恰提供了将韩国文化IP转化为全球规模机构级链上金融产品所需的智能基础设施。我们将携手构建韩流基础设施金融的操作系统。"- John K. Park，Demora Foundation / JP3E Holdings Inc. 董事长兼首席执行官关于 Datavault AI Inc. (纳斯达克代码：DVLT)Datavault AI Inc. (纳斯达克代码：DVLT) 是一家以人工智能为驱动的数据变现、RWA 通证化及 Web 3.0 基础设施公司，总部位于宾夕法尼亚州费城市场街 2005 号 One Commerce Square 大厦 2400 室（邮编 19103）。DVLT提供企业级平台，包括Information Data Exchange®（数字孪生/NIL认证）、Data Vault®、DataValue®和DataScore®人工智能代理，以及由高性能计算（HPC）驱动的数据估值和安全变现基础设施，业务覆盖金融科技、医疗保健、房地产以及体育与娱乐垂直领域——包括整个K-娱乐产业。首席执行官：纳撒尼尔·布拉德利。网站：www.datavaultsite.com关于 Demora 基金会Demora 基金会是 Demora Chain 的机构治理实体——Demora Chain 是一个基于以太坊的双 OP Stack Layer 2 解决方案（目标：560,000+ TPS，美元计价 gas 模型），专为机构级别的稳定币金融、RWA 通证化和 VWA（虚拟财富资产）创建而设计。Demora基金会管理着DMR-LIVE韩流娱乐RWA代币化协议，该协议是其K2Global创新“韩流城市”部署的旗舰产品。Demora基金会注册于特拉华州，由JP3E Holdings Inc.管理。网站：demora.foundation媒体联系人：John K. Park，董事长兼首席执行官 - JP3E Holdings Inc. / Demora基金会John.park@jp3e.com  | www.jp3e.com  | demora.foundationAlan Wallace，公关总监 - Datavault AI / marketing@dvlt.ai投资者联系Edward Barger，投资者关系副总裁 - Datavault AI，ir@dvlt.ai - ebarger@dvlt.ai来源：Datavault AI Inc Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com